The ZNF304-integrin axis protects against anoikis

• Published in: Nature communications 2015-06, Vol.6, p.7351-7351
• Main Authors: Aslan, Burcu, Monroig, Paloma, Hsu, Ming-Chuan, Pena, Guillermo Armaiz, Rodriguez-Aguayo, Cristian, Gonzalez-Villasana, Vianey, Rupaimoole, Rajesha, Nagaraja, Archana Sidalaghatta, Mangala, Selanere, Han, Hee-Dong, Yuca, Erkan, Wu, Sherry Y., Ivan, Cristina, Moss, Tyler J., Ram, Prahlad T., Wang, Huamin, Gol-Chambers, Alexandra, Ozkayar, Ozgur, Kanlikilicer, Pinar, Fuentes-Mattei, Enrique, Kahraman, Nermin, Ozpolat, Bulent, Tucker, Susan, Hung, Mien-Chie, Baggerly, Keith, Bartholomeusz, Geoffrey, Calin, George, Sood, Anil K., Lopez-Berestein, Gabriel
• Format: Article
• Language: English
• ISSN: 2041-1723
• DOI: 10.1038/ncomms8351

Ovarian cancer is a highly metastatic disease, but no effective strategies to target this metastatic process currently are known. Here, an integrative computational analysis of The Cancer Genome Atlas ovarian cancer dataset coupled with experimental validation identified a novel zinc finger transcription factor ZNF304 as one of the key factors for ovarian cancer metastasis. High tumoral ZNF304 expression was associated with poor overall survival in ovarian cancer patients. Through reverse phase protein array analysis, we demonstrated that ZNF304 promotes multiple proto-oncogenic pathways important for cell survival, migration, and invasion. ZNF304 transcriptionally regulates β1 integrin, which subsequently regulates Src/focal adhesion kinase and paxillin and prevents anoikis. In vivo delivery of ZNF304 siRNA by a novel dual assembly nanoparticle led to sustained gene silencing for 14 days, increased anoikis, and reduced tumor growth in orthotopic mouse models of ovarian cancer. Taken together, ZNF304 is a novel transcriptional regulator of β1 integrin, promotes cancer cell survival, and protects against anoikis in ovarian cancer.